Latest available resultsQuarter ended June 30, 202610-Q · August 5, 2026
Filed with the SECELI LILLY & Co
LLYPharma & biotech
Next reportOctober 29, 2026Analyst forecast 9.877 $/share
Revenue
$22.97B
▲ +47.7% vs prior year% YoY
Net income
$7.09B
▲ +25.3% vs prior year% YoY
EPS
7.94$
▲ +26.2% vs prior year% YoY
Net margin
30.9%
▼ -5.5 percentage points vs prior year pp YoY
Revenue▲ +47.7 %
Margins (% of revenue)GrossOperating N/ANet
Net income▲ +25.3 %
EPS▲ +26.2 %
View financial tableQuarter ended June 30, 2026
| Metric | Value | Context |
|---|---|---|
| Operations | ||
| Revenue | $22.97B | |
| Gross profit | $19.71B | 85.8 % |
| Operating income | — | never filed |
| Net income | $7.09B | 30.9 % |
| R&D | — | |
| EPS (diluted) | 7.94 $ | |
| Balance sheet | ||
| Assets | $142.28B | |
| Liabilities | $108.40B | |
| Equity | $33.88B | |
| Cash | $8.95B | |
| Capital | ||
| Shares outstanding | 941.36M | as of 2026-08-03 |
| Public float | — | |